Caspofungin is an echinocandin antifungal agent used as first-line therapy for the treatment of invasive candidiasis. The maintenance dose is adapted to body weight (BW) or liver function (Child-Pugh score B or C). We aimed to study the pharmacokinetics of caspofungin and assess pharmacokinetic target attainment for various dosing strategies.
Caspofungin pharmacokinetic data from 21 intensive care unit (ICU) patients was available. A population pharmacokinetic model was developed. Various dosing regimens (loading dose/maintenance dose) were simulated: licensed regimens (I) 70/50 mg (for BW <80 kg) or 70/70 mg (for BW >80 kg); and (II) 70/35 mg (for Child-Pugh score B); and adapted regimens (III) 100/50 mg (for Child-Pugh score B); (IV) 100/70 mg; and (V) 100/100 mg. Target attainment based on a preclinical pharmacokinetic target for Candida albicans was assessed for relevant minimal inhibitory concentrations (MICs).
A two-compartment model best fitted the data. Clearance was 0.55 L/h and the apparent volumes of distribution in the central and peripheral compartments were 8.9 and 5.0 L, respectively. The median area under the plasma concentration–time curve from time zero to 24 h on day 14 for regimens I–V were 105, 65, 93, 130, and 186 mg·h/L, respectively. Pharmacokinetic target attainment was 100 % (MIC 0.03 µg/mL) irrespective of dosing regimen but decreased to (I) 47 %, (II) 14 %, (III) 36 %, (IV) 69 %, and (V) 94 % for MIC 0.125 µg/mL.
The caspofungin maintenance dose should not be reduced in non-cirrhotic ICU patients based on the Child-Pugh score if this classification is driven by hypoalbuminemia as it results in significantly lower exposure. A higher maintenance dose of 70 mg in ICU patients results in target attainment of >90 % of the ICU patients with species with an MIC of up to 0.125 µg/mL.
European Medicines Agency. Summary of product characteristics: Cancidas 2011 [last updated 26 Oct 2014]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000379/WC500021033.pdf. Accessed 27 Mar 2015.
US Food and Drug Administration. Cancidas label information 2014 [last updated 26 Oct 2014]. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021227s033lbl.pdf. Accessed 27 Mar 2015.
Beal SL, Sheiner LB, Boeckmann A. NONMEM user’s guides (1989–2006). Ellicott City: Icon Development Solutions; 2006.
R Development Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2013.
Bruggemann RJ, Van Der Velden WJ, Knibbe CA, Colbers A, Hol S, Burger DM, et al. A rationale for reduced-frequency dosing of anidulafungin for antifungal prophylaxis in immunocompromised patients. J Antimicrob Chemother. 2015;70(4):1166–74. PubMed
Pfaller MA, Diekema DJ, Andes D, Arendrup MC, Brown SD, Lockhart SR, et al. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updat. 2011;14(3):164–76. CrossRefPubMed
European Medicines Agency (EMA). Cancidas: EPAR scientific discussion 2004. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000379/WC500057186.pdf. Accessed 27 Mar 2015.
Blot SI, Pea F, Lipman J. The effect of pathophysiology on pharmacokinetics in the critically ill patient–concepts appraised by the example of antimicrobial agents. Adv Drug Deliv Rev. 2014;20(77):3–11. CrossRef
Betts RF, Nucci M, Talwar D, Gareca M, Queiroz-Telles F, Bedimo RJ, et al. A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis. 2009;48(12):1676–84. CrossRefPubMed
Radboud University. Pharmacokinetics of caspofungin (Cancidas ®) given intravenously as therapy to patients with an invasive fungal infection in the intensive care unit—a search for co-variates (CASCADE) [ClinicalTrials.gov identifier NCT01533558]. US National Institutes of Health, ClinicalTrials.gov. https://www.clinicaltrials.gov. Accessed 7 Nov 2015.
- Dose Reduction of Caspofungin in Intensive Care Unit Patients with Child Pugh B Will Result in Suboptimal Exposure
Lisa C. Martial
Roger J. M. Brüggemann
Jeroen A. Schouten
Henk J. van Leeuwen
Arthur R. van Zanten
Dylan W. de Lange
Eline W. Muilwijk
Paul E. Verweij
David M. Burger
Rob E. Aarnoutse
Thomas P. C. Dorlo
- Springer International Publishing